Yi Zi-Lu, Yang Bei-Bei, Zhang Jia-Ning, Zhao Meng-Jun, Shen Meng-Lu, Zhou Xi-Rui, Liu Hong
The Second Surgical Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Breast Cancer Res Treat. 2025 Jul;212(2):189-193. doi: 10.1007/s10549-025-07712-8. Epub 2025 May 14.
To raise awareness of radiation recall dermatitis (RRD) in the context of radiotherapy combined with abemaciclib, and to explore its potential mechanisms, characteristics, and treatment options.
We conducted a case series study reporting the first instances of RRD induced by abemaciclib in two women with locally advanced luminal breast cancer. Both patients experienced skin reactions in previously irradiated areas following abemaciclib administration. Additionally, a comprehensive literature review was performed to analyze the potential mechanisms of RRD, characteristics of radiotherapy, triggering drugs, and available treatments.
The case series demonstrated that abemaciclib can induce RRD in patients who have undergone radiotherapy. Both patients experienced significant skin reactions, which were successfully managed and resolved upon rechallenge with abemaciclib. The literature review highlighted the importance of recognizing RRD as a potential adverse effect of cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), emphasizing the need for careful monitoring and appropriate management strategies.
Radiation recall dermatitis is a potential adverse effect of abemaciclib in patients receiving radiotherapy for breast cancer. Our findings underscore the importance of awareness and vigilance in managing patients on CDK4/6is.
提高对放疗联合阿贝西利治疗背景下放射性回忆性皮炎（RRD）的认识，并探讨其潜在机制、特征及治疗方案。
我们开展了一项病例系列研究，报告了两例局部晚期腔面型乳腺癌女性患者中由阿贝西利诱发的首例RRD。两名患者在服用阿贝西利后，先前接受过放疗的部位均出现了皮肤反应。此外，还进行了全面的文献综述，以分析RRD的潜在机制、放疗特征、引发药物及可用治疗方法。
该病例系列表明，阿贝西利可在接受过放疗的患者中诱发RRD。两名患者均出现了明显的皮肤反应，在再次使用阿贝西利时成功得到处理并缓解。文献综述强调了将RRD识别为细胞周期蛋白依赖性激酶4/6抑制剂（CDK4/6is）潜在不良反应的重要性，强调了仔细监测和适当管理策略的必要性。
放射性回忆性皮炎是接受乳腺癌放疗患者使用阿贝西利时的一种潜在不良反应。我们的研究结果强调了在管理接受CDK4/6is治疗的患者时提高认识和保持警惕的重要性。
